TABLE 2.
Total (n) | Patients with BRCA1 pathogenic mutations (n) | Patients with BRCA2 pathogenic mutations (n) | Patients with BRCA1/BRCA2 pathogenic comutations (n) | Patients with BRCA1/BRCA2 pathogenic mutations (n, %) | ||
---|---|---|---|---|---|---|
Patients, n | 3094 | 55 | 97 | 4 | 156 (5.0) | |
Cancer type | ||||||
BRCA‐associated cancer | Breast | 196 | 2 | 15 | 0 | 17 (8.7) |
Ovary/fallopian tube/peritoneal | 253 | 26 | 7 | 0 | 33 (13.0) | |
Pancreas | 263 | 1 | 12 | 0 | 13 (4.9) | |
Prostate | 254 | 3 | 30 | 0 | 33 (13.0) | |
Total | 966 | 32 | 64 | 0 | 96 (9.9) | |
Non‐BRCA‐associated cancer | Colorectal | 539 | 4 | 6 | 1 | 11 (2.0) |
Biliary | 229 | 3 | 4 | 2 | 9 (3.9) | |
Central nervous system | 152 | 1 | 4 | 0 | 5 (3.3) | |
Sarcoma | 138 | 1 | 3 | 0 | 4 (2.9) | |
Uterus | 115 | 3 | 2 | 1 | 6 (5.2) | |
Uterine cervix | 114 | 1 | 2 | 0 | 3 (2.6) | |
NSCLC | 105 | 0 | 3 | 0 | 3 (2.9) | |
Head and neck | 99 | 0 | 1 | 0 | 1 (1.0) | |
Stomach | 85 | 2 | 2 | 0 | 4 (4.7) | |
Thyroid | 78 | 0 | 0 | 0 | 0.0 | |
Skin | 75 | 1 | 0 | 0 | 1 (1.3) | |
Unknown primary | 66 | 5 | 2 | 0 | 7 (10.6) | |
Esophagus | 63 | 0 | 3 | 0 | 3 (4.8) | |
Urinary | 63 | 1 | 1 | 0 | 2 (3.2) | |
Kidney | 23 | 0 | 0 | 0 | 0.0 | |
Thymus | 14 | 0 | 0 | 0 | 0.0 | |
Adrenal gland | 11 | 0 | 0 | 0 | 0.0 | |
Duodenum | 11 | 1 | 0 | 0 | 1 (9.1) | |
SCLC | 11 | 0 | 0 | 0 | 0.0 | |
Neuroendocrine carcinoma | 9 | 0 | 0 | 0 | 0.0 | |
GIST | 8 | 0 | 0 | 0 | 0.0 | |
Neuroendocrine tumor | 8 | 0 | 0 | 0 | 0.0 | |
Mesothelioma | 7 | 0 | 0 | 0 | 0.0 | |
Liver | 6 | 0 | 0 | 0 | 0.0 | |
Soft tissue | 6 | 0 | 0 | 0 | 0.0 | |
Vagina | 4 | 0 | 0 | 0 | 0.0 | |
Testis | 2 | 0 | 0 | 0 | 0.0 | |
Others | 87 | 0 | 0 | 0 | 0.0 | |
Total | 2128 | 23 | 33 | 4 | 60 (2.8) |
Abbreviations: GIST, gastrointestinal stromal tumor; NSCLC, non‐small‐cell lung cancer; SCLC, small‐cell lung cancer.